Regulus Therapeutics (NASDAQ:RGLS)‘s stock had its “hold” rating reiterated by equities researchers at Wedbush in a report released on Thursday, AnalystRatings.com reports. They presently have a $1.00 price target on the biopharmaceutical company’s stock. Wedbush’s price objective points to a potential downside of 16.67% from the company’s previous close. Wedbush also issued estimates for Regulus Therapeutics’ Q2 2019 earnings at ($0.19) EPS, Q3 2019 earnings at ($0.27) EPS, Q4 2019 earnings at ($0.25) EPS, FY2019 earnings at ($1.41) EPS, Q1 2020 earnings at ($0.26) EPS, Q2 2020 earnings at ($0.27) EPS, Q3 2020 earnings at ($0.28) EPS, Q4 2020 earnings at ($0.29) EPS and FY2020 earnings at ($1.09) EPS.
Other equities analysts have also issued reports about the stock. Zacks Investment Research upgraded shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research note on Friday, March 29th. Wells Fargo & Co dropped their price target on shares of Regulus Therapeutics from $6.00 to $1.50 and set a “market perform” rating on the stock in a research note on Tuesday, March 19th. Finally, ValuEngine lowered shares of Regulus Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the stock. Regulus Therapeutics presently has an average rating of “Hold” and an average price target of $1.06.
Shares of RGLS stock traded down $0.13 during trading hours on Thursday, reaching $1.20. 2,671 shares of the stock were exchanged, compared to its average volume of 255,743. Regulus Therapeutics has a 12-month low of $0.80 and a 12-month high of $9.48. The firm has a market capitalization of $13.27 million, a price-to-earnings ratio of -0.21 and a beta of 2.26.
In other Regulus Therapeutics news, Director Pascale Witz bought 29,630 shares of the stock in a transaction dated Tuesday, May 7th. The shares were acquired at an average cost of $1.08 per share, for a total transaction of $32,000.40. Following the completion of the transaction, the director now owns 37,849 shares in the company, valued at approximately $40,876.92. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Peter J. Barris bought 1,136,704 shares of the stock in a transaction dated Tuesday, May 7th. The shares were acquired at an average price of $1.08 per share, for a total transaction of $1,227,640.32. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 1,199,528 shares of company stock worth $1,295,490 and sold 11,805 shares worth $11,569. Corporate insiders own 5.40% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in RGLS. Jane Street Group LLC bought a new stake in Regulus Therapeutics during the first quarter worth $64,000. Renaissance Technologies LLC lifted its stake in Regulus Therapeutics by 72.2% during the first quarter. Renaissance Technologies LLC now owns 275,693 shares of the biopharmaceutical company’s stock worth $281,000 after purchasing an additional 115,625 shares during the last quarter. Wedbush Securities Inc. lifted its stake in Regulus Therapeutics by 32.8% during the first quarter. Wedbush Securities Inc. now owns 43,489 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 10,751 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in Regulus Therapeutics during the first quarter worth $68,000. Institutional investors and hedge funds own 25.17% of the company’s stock.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
Recommended Story: Diversification Important in Investing
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.